Since the avian cancer virus experiment in 2011, scientists have confirmed seven different viruses that cause about ten to fifteen percent of human cancer globally. Notably, these distinct viruses have revealed unprecedented links between innate immunities as well as sensors and tumour suppressors, implying that they control both cancer and viral infections.
Apparently, these varied cancers remain to be a substantial health challenge, especially in developing economies, alongside the underserved and immuno-suppressed individuals in developed economies.
Among the several human tumour viruses evidenced by several scientists and scholars, this paper will explore the Epstein-Barr virus (EBV), the Hepatitis B virus (HBV) and the Human papilloma virus (HPV) along with their distinct ways by which they cause tumours.
Table of Contents
1. Introduction
2. Epstein-Barr virus (EBV)
2.1 EBV Microbe Description
2.2 EBV Disease Explanation
2.3 Course of the EBV Infection
2.4 Current Research and Future Research/Directions
2.5 World Relevance
3. Hepatitis B virus (HBV)
3.1 HBV Microbe Description
3.2 HBV Disease Explanation
3.3 HBV Disease Course
3.4 Interaction between HBV Microbe and Host
3.5 HBV Current Research and Future Research/Directions
3.6 Global Significance
4. Human Papilloma Virus (HPV)
4.1 HPV Microbe Description
4.2 Description of HBV Infection
4.3 The Course of HPV Infection
4.4 Current Research and Future Research/Directions
4.5 Global Significance
5. Conclusion
Objectives and Topics
This paper examines the role of specific viruses in the development of human tumors, aiming to provide insights into their pathogenic mechanisms and potential therapeutic targets. By analyzing the Epstein-Barr virus, Hepatitis B virus, and Human Papilloma Virus, the study highlights how these viral agents interact with host cells to induce malignancies and how current medical research addresses these health challenges.
- Viral pathogenesis and tumor development
- Molecular biology of EBV, HBV, and HPV
- Host-virus immune system interactions
- Advancements in prophylactic and therapeutic vaccination
- Global public health impact and clinical management strategies
Excerpt from the Book
EBV Microbe Description
The EBV, which is also termed as the human herpes virus 4 (HHV4) was described fifty-three years after the initial experiments of Rous; in 1964 in the identification of the EBV particles in cell lines from Burkitt’s lymphoma African patients (Moore & Chang, 2010). The EBV is a herpes virus that contains a large double-stranded DNA genome, and just like all other herpesviruses, it encodes enzymes that are involved in DNA replication as well as repair and nucleotide biosynthesis. It also possesses the ability to establish latency in B lymphocytes, reactivating into a lytic cycle (Liao, 2006). In other words, EBV infects and stays in certain WBCs (white blood cells) in the body known as B lymphocytes (B cells), and it is renowned in causing infectious mononucleosis or naturally occurring human tumours.
Chapter Summaries
1. Introduction: This chapter introduces the significant global burden of viral-induced cancers and outlines the intent to explore the mechanisms of specific oncogenic viruses.
2. Epstein-Barr virus (EBV): This section details the biological characteristics of EBV, its role in diseases like Burkitt’s lymphoma, and current efforts in immune therapy and vaccine development.
3. Hepatitis B virus (HBV): This chapter covers the genomic structure of the Hepatitis B virus, its progression into hepatocellular carcinoma, and the importance of global immunization policies.
4. Human Papilloma Virus (HPV): This part explores the viral lifecycle of HPV, its link to cervical cancer, and the promise of prophylactic vaccines in reducing cancer mortality.
5. Conclusion: The concluding chapter summarizes the potential of using viral gene products as specific therapeutic targets to improve upon traditional cancer treatment modalities.
Keywords
Viruses, Tumours, Epstein-Barr virus, Hepatitis B virus, Human Papilloma Virus, Oncology, Immunology, Vaccination, DNA genome, Malignancy, Cellular transformation, Pathogenesis, Public health, Cancer research, Prophylactic vaccine.
Frequently Asked Questions
What is the primary focus of this paper?
The paper focuses on the biological pathways through which specific viruses, namely EBV, HBV, and HPV, cause human tumors and how these mechanisms inform potential cancer therapies.
Which viruses are specifically analyzed in this research?
The study provides a detailed analysis of the Epstein-Barr virus (EBV), Hepatitis B virus (HBV), and the Human Papilloma Virus (HPV).
What is the central research goal regarding these viruses?
The goal is to understand their distinct ways of causing tumors and to evaluate current and future research directions, particularly regarding vaccines and immune-based treatments.
What scientific methods are discussed in the context of treatment?
The paper discusses traditional treatments like surgery, chemotherapy, and radiation, as well as modern approaches like adoptive T-cell transfer and recombinant viral vector vaccines.
What is covered in the main body regarding the virus lifecycles?
The main body treats the viral structure (microbe description), disease explanation, infection progression, and the specific interaction between the viral pathogens and the host immune system.
Which keywords best describe this study?
Key terms include oncogenic viruses, malignancy, immune therapy, vaccination, DNA genome, and cellular transformation.
How does EBV maintain its presence in the human body?
EBV establishes latency in B lymphocytes, allowing it to persist in the body and potentially reactivate into a lytic cycle.
Why is HPV vaccination particularly important for cervical cancer?
Because HPV 16 and 18 are the causative agents for approximately 70% of cervical cancers, making prophylactic vaccination a highly effective tool for prevention.
What challenges do existing HBV vaccines face?
Current challenges include the limitations of dosing schedules and the need to integrate HBV immunization with other required vaccines to improve global coverage.
- Citation du texte
- Business Administrator Mutinda Jackson (Auteur), 2018, The different ways in which viruses cause tumors, Munich, GRIN Verlag, https://www.grin.com/document/429538
